Truetide (LSE:TRUE), the AIM-listed investment company focused on technology and knowledge-intensive businesses, updated investors on two holdings, wholly owned Paraytec and Gyrometric Systems, in which it holds a 21.43% stake.
Paraytec is developing the CX300 instrument to speed diagnosis of bacteraemia, a marker present in most sepsis patients, and has already shown the device can distinguish Gram-positive from Gram-negative bacteria in roughly 90 minutes, against 24 to 48 hours for the standard Gram test.
The company's latest breakthrough addresses a specific technical hurdle: finding a molecule that binds selectively to Gram-positive bacteria without triggering false positives from protein aggregation.
Paraytec has now identified small molecules that bind directly to a motif unique to Gram-positive bacteria, showing stable, selective binding in standard laboratory tests.
The next step is confirming detection sensitivity in clinically relevant fluids such as blood and urine.
Separately, Gyrometric completed the US-UK Large Journal Bearing Validation and Measurement Project, demonstrating that its patented technology can monitor large journal bearings, a component where conventional vibration-based monitoring fails.
As wind turbines scale up, drivetrains are shifting from rolling element bearings to journal bearings, which carry higher loads, have fewer moving parts and can potentially be refurbished in situ rather than requiring full turbine dismantling.
Gyrometric's technology measures shaft movement directly, filling the monitoring gap left by vibration-based systems that rely on fault frequencies rolling elements generate.
The project, tested at Kingsbury in Philadelphia, was backed by just under £300,000 from Innovate UK's £570,000 total budget, alongside US funding from the National Offshore Wind Research and Development Consortium.
News Intelligence what this means for the company
Truetide reported incremental progress at two portfolio companies: Paraytec identified molecules that bind selectively to Gram-positive bacteria, advancing its sepsis diagnostic instrument toward clinical validation in blood and urine; and Gyrometric completed a £300,000 UK-backed project demonstrating its bearing monitoring technology works where vibration-based systems fail. Neither announcement signals a near-term commercial milestone—both remain in validation or project-completion phases with next steps still pending.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
